Operator Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release ... The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure ...

Novartis Q4 earnings beat estimates with sales up 16%, driven by strong demand for Entresto, Kesimpta, and Cosentyx. CEO Narasimhan reportedly downplays Entresto's U.S. patent expiration ...

Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF100.00. According to TipRanks, Welford is a 4-star analyst ...

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth. After signing 30 deals ...

Empowering All Women to Own Their Breast Health "Novartis has been raising the bar in breast cancer care for the past 30+ years, most recently advancing a new treatment option for the broadest ...

logo will not comply with upcoming new requirements ... leading many municipalities and brands to no longer use it. “Ensuring accessibility is about equity and inclusion,” Gauvin said.

🖼️ Image Toolbox is a powerful app for advanced image manipulation. It offers dozens of features, from basic tools like crop and draw to filters, OCR, and a wide range of image processing options ...

Novartis AG’s plan to sell its 70.6% stake in Novartis India is on track, CEO Vas Narasimhan confirmed at the World Economic Forum in Davos. Speaking to CNBC-TV18, he emphasised the company’s ...

Greece on Monday prosecuted a pair of protected witnesses for alleged perjury in a long-running bribery probe involving the Swiss pharmaceutical firm Novartis, a justice source said. The man and woman ...

Novartis won an order from a U.S. appeals court in Washington on Thursday temporarily blocking MSN Pharmaceuticals from launching a generic version of Novartis' heart-failure drug Entresto, per a ...

The roller-coaster ride for Novartis—as it uses every bit of its legal muscle to extend Entresto's market exclusivity—took another zig on Thursday with a federal appellate court blocking the ...